Life Sciences

New York Times’ seizure call shows how far the tide is turning against pharma IP

The newspaper’s controversial proposal is stark demonstration of the mounting patent pressure the life sciences sector is under in the US

<em>New York Times</em>’ seizure call shows how far the tide is turning against pharma IP
12 Jul 2019

Delhi judge orders IP appeal board to start hearing cases again

The body has been paralysed by vacancies for years and more than 600 appeals of patent office decisions are in limbo

11 Jul 2019

New analysis shows impact that “blockbuster” decisions are having on patent litigation

RPX data highlights big drop in success of early 101 challenges in district court cases; if trend continues would point to shift in balance of power back to IP owners

Latest

View all
11 Jul 2019

CAFC says Congress or SCOTUS must address diagnostics patentability controversy

Decision denying en banc rehearing of much-watched Athena case means that hopes for 101 reform now hinge on legislators and the Supreme Court Read more

10 Jul 2019

All the big life sciences IP developments in June

Our round-up of the major patent issues affecting pharma and biotech that emerged on the legal, market and policy fronts last month Read more

9 Jul 2019

Incorrectly naming an RPI will not derail an IPR, Federal Circuit rules

In Mayne Pharma, the court upheld a PTAB final written decision invalidating a patent despite the owner’s objection that all real-parties-in-interest were not properly named in the original review petition Read more

8 Jul 2019

Intel, Alphabet and Qualcomm among big fallers as largest US IP owners cut back on patenting

Latest ranking from IPO of top 300 companies shows an overall decline in the market as the mantra of quality over quantity continues to take effect Read more

News

View all
23 Jun 2019

Rubio’s Huawei proposal should worry US tech, pharma companies

Letting the executive branch neutralise patents whose owners it doesn’t like would weaken the US patent system and invite retaliation by China Read more

19 Jun 2019

What to do with conflicting testimony on patent eligibility

Former CAFC Chief Judge Michel: “If the public debate is confused by unreliable statements of ill-informed or overzealous advocates, the US will decline and its future will fade.” Read more

17 Jun 2019

IPBC Global 2019 – Day One highlights

All the big stories from the first full day of the world’s pre-eminent conference about IP value creation Read more

17 Jun 2019

Why it's time for the world of patents to embrace diversity and gender equality

Special IAM boardroom session at IPBC Global 2019 focuses on how to get more women involved in senior positions in the global IP market - and why everyone will win when it happens Read more

Analysis

View all
5 Jul 2019

Get ready for the first CRISPR patent pool

In an exclusive interview, MPEG LA’s Kristin Neuman says that a pool is on its way despite the UCal v Broad stand-off and talks about the future of licensing in biotech’s ‘golden age’ Read more

3 Jul 2019

Law firm’s patent attorney deal shows changing face of IP practice in the UK

Lewis Silkin’s acquisition of Ablett & Stebbing is a first and demonstrates just how far things have moved in a once conservative market Read more

2 Jul 2019

AbbVie’s Allergan play designed to mitigate Humira patent cliff

The $63 billion purchase is designed to mitigate the effects of losing the exclusive rights to the world’s best selling drug Read more

1 Jul 2019

Slump at the PTAB continues with first half numbers showing big drop in new reviews

Data suggests PTO director Iancu’s IPR reforms are continuing to bite; while despite jump in Q2, district court litigation remains broadly flat for first six months of 2019 Read more

Insights

View all
24 May 2019

IP market news highlights

Some of the major news stories carried on the IAM platform from March to mid-May. Read more

1 Apr 2019

IP market news highlights

The big stories from the IAM platform in February and March. Read more